Bio-Techne stock price target lowered to $75 by Scotiabank

Investing.com - Scotiabank (TSX:BNS) lowered its price target on Bio-Techne Corp. (NASDAQ:TECH) to $75.00 from $90.00 on Friday, while maintaining a Sector Outperform rating on the stock. The company, currently trading at $53.92 with a market capitalization of $8.41 billion, is trading at a high earnings multiple according to InvestingPro data.

The price target reduction reflects Scotiabank’s view that Bio-Techne faces "the widest range of possible growth rates" in fiscal year 2026, given its relatively higher exposure to U.S. A&G and broader exposure across the pharmaceutical and biotech sectors.

Despite the near-term caution, Scotiabank believes Bio-Techne has "greater potential for outsized growth compared to its peers" over the longer term due to its size and strategic focus on fast-growing areas in life science tools and diagnostics. InvestingPro analysis reveals the company maintains strong financial health with a robust current ratio of 3.71 and has consistently paid dividends for 18 consecutive years.

These growth opportunities include proteomic analysis, spatial biology, exosome-based liquid biopsy technology, and cell production technology for cell and gene therapy.

Scotiabank also highlighted Bio-Techne’s "industry-leading margins" and noted there is "further headroom for improvement over the next several years."

In other recent news, Bio-Techne Corp reported its third-quarter earnings for 2025, with an adjusted earnings per share (EPS) of $0.56, surpassing the forecast of $0.51. However, the company’s revenue slightly missed expectations, coming in at $316.2 million compared to the projected $317.5 million. Despite these mixed results, the company’s Protein Sciences segment showed robust growth, contributing significantly to its performance. Analysts at Benchmark maintained a Buy rating with a $75 price target, although they adjusted their revenue and earnings estimates for the fourth quarter due to the impact of U.S. tariffs and potential NIH funding cuts.

Additionally, Wells Fargo (NYSE:WFC) initiated coverage on Bio-Techne with an Overweight rating and a price target of $59, citing the company’s strong financial position and potential for strategic acquisitions. Stifel reiterated a Hold rating with a $60 price target, noting the company’s pharmaceutical segment is expected to see mid-single-digit growth by year-end. Bio-Techne’s management remains optimistic about re-accelerating growth and outperforming industry peers, as reported by Stifel. These developments reflect the company’s ongoing efforts to navigate economic pressures and maintain its strategic growth initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.